Yields and immunomodulatory effects of pneumococcal membrane vesicles differ with the bacterial growth phase


Posted: 2021-11-01 19:00:00
Adv Healthc Mater . 2021 Nov 1;e2101151. doi: 10.1002/adhm.202101151. Online ahead of print. Affiliations Expand Affiliations 1 M. Mehanny, G. Fuhrmann, Helmholtz Institute for Pharmaceutical Research Saarland, Biogenic Nanotherapeutics Group, Campus E8.1- 66123, Saarbrücken, Germany. 2 M. Mehanny, G. Fuhrmann, C-M. Lehr, Department of Pharmacy, Saarland University, Campus E8.1- 66123, Saarbrücken, Germany. 3 M. Mehanny, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University - 11566, Cairo, Egypt. 4 T. Kroniger, D. Becher, Center for Functional Genomics of Microbes, Department of Microbial Proteomics, Institute of Microbiology, University Greifswald, Greifswald, Germany. 5 M. Koch, INM - Leibniz Institute for New Materials, Campus D2.2 - 66123, Saarbrücken, Germany. 6 J. Hoppstädter, A.K. Kiemer, Department of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany. 7 C-M Lehr, Helmholtz Institute for Pharmaceutical Research Saarland, Drug Delivery Department, Campus E8.1- 66123, Saarbrücken, Germany. Item in Clipboard Mina Mehanny et al. Adv Healthc Mater. 2021. Show details Display options Display options Format Adv Healthc Mater . 2021 Nov 1;e2101151. doi: 10.1002/adhm.202101151. Online ahead of print. Affiliations 1 M. Mehanny, G. Fuhrmann, Helmholtz Institute for Pharmaceutical Research Saarland, Biogenic Nanotherapeutics Group, Campus E8.1- 66123, Saarbrücken, Germany. 2 M. Mehanny, G. Fuhrmann, C-M. Lehr, Department of Pharmacy, Saarland University, Campus E8.1- 66123, Saarbrücken, Germany. 3 M. Mehanny, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University - 11566, Cairo, Egypt. 4 T. Kroniger, D. Becher, Center for Functional Genomics of Microbes, Department of Microbial Proteomics, Institute of Microbiology, University Greifswald, Greifswald, Germany. 5 M. Koch, INM - Leibniz Institute for New Materials, Campus D2.2 - 66123, Saarbrücken, Germany. 6 J. Hoppstädter, A.K. Kiemer, Department of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, Germany. 7 C-M Lehr, Helmholtz Institute for Pharmaceutical Research Saarland, Drug Delivery Department, Campus E8.1- 66123, Saarbrücken, Germany. Item in Clipboard CiteDisplay options Display options Format Abstract Streptococcus pneumoniae infections are a leading cause of death worldwide. Bacterial membrane vesicles (MVs) are promising vaccine candidates because of the antigenic components of their parent microorganisms. Pneumococcal MVs exhibit low toxicity towards several cell lines, but their clinical translation requires a high yield and strong immunogenic effects without compromising immune cell viability. MVs were isolated during either the stationary phase (24 h) or death phase (48 h), and their yields, immunogenicity and cytotoxicity in human primary macrophages and dendritic cells were investigated. Death-phase vesicles showed higher yields than did stationary-phase vesicles. Both vesicle types displayed acceptable compatibility with primary immune cells and several cell lines. Both vesicle types showed comparable uptake and enhanced release of the inflammatory cytokines, tumor necrosis factor and interleukin-6, from human primary immune cells. Proteomic analysis revealed similarities in vesicular immunogenic proteins such as pneumolysin, pneumococcal surface protein A, and IgA1 protease in both vesicle types, but stationary-phase MVs showed significantly lower autolysin levels than did death-phase MVs. Although death-phase vesicles produced higher yields, they lacked superiority to stationary-phase vesicles as vaccine candidates owing to their similar antigenic protein cargo and comparable uptake into primary human immune cells. This article is protected by copyright. All rights reserved. Keywords: bacterial membrane vesicles; dendritic cells; extracellular vesicles; pneumococci; primary macrophages; proteomics; vaccines. This article is protected by copyright. All rights reserved. [x] Cite Copy Format: Send To [x]

参考サイト PubMed: exsome


Powered by Stromvergleich


バイオクイックニュース日本語版:エクソソーム特集

バイオクイックニュース日本語版
9月 18, 2019 バイオアソシエイツ

創傷治療治験中のペプチド変異体が、心臓発作の『バイスタンダー効果』による損傷を防御する可能性。研究グループはエクソソームによる防御ペプチドの送達を検討中。

健康な心筋組織を保護することで損傷を減らす心臓発作の直後に服用できる薬があると想像して欲しい。 心臓発作が起きた場合、心臓の専門医は、「時は筋肉なり」と言うと、バージニア工科大学カリリオン心臓医療センター・フラリン生物医学研究所のディレクターであるRobert Gourdie博士(写真)は語った。 血流によって酸素が供給されないと、心臓細胞はすぐに死ぬ。…

ゲスト 574人 と メンバー 2人 がオンラインです